切换至 "中华医学电子期刊资源库"

中华消化病与影像杂志(电子版) ›› 2018, Vol. 08 ›› Issue (02) : 61 -65. doi: 10.3877/cma.j.issn.2095-2015.2018.02.004

所属专题: 文献

临床研究

生长抑素联合前列地尔治疗重症急性胰腺炎的疗效及对部分血清炎症因子的影响
杨德红1, 邵庆华2,()   
  1. 1. 650000 昆明,云南省第一人民医院生殖医学中心
    2. 650011 昆明,云南省第三人民医院普外科
  • 收稿日期:2017-10-20 出版日期:2018-04-01
  • 通信作者: 邵庆华

Clinical effect of somatostatin combined with alprostadil for patients with severe acute pancreatitis and its effect on the serum inflammatory factors

Dehong Yang1, Qinhua Shao2,()   

  1. 1. Center of Reproductive Medicine, First People′s Hospital of Yunnan Province, Kunming 650000, China
    2. Department of General Surgery, Third People′s Hospital of Yunnan Province, Kunming 650011, China
  • Received:2017-10-20 Published:2018-04-01
  • Corresponding author: Qinhua Shao
  • About author:
    Corresponding author: Shao Qinhua, Email:
引用本文:

杨德红, 邵庆华. 生长抑素联合前列地尔治疗重症急性胰腺炎的疗效及对部分血清炎症因子的影响[J/OL]. 中华消化病与影像杂志(电子版), 2018, 08(02): 61-65.

Dehong Yang, Qinhua Shao. Clinical effect of somatostatin combined with alprostadil for patients with severe acute pancreatitis and its effect on the serum inflammatory factors[J/OL]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2018, 08(02): 61-65.

目的

观察生长抑素联合前列地尔治疗重症急性胰腺炎的疗效及对部分血清炎症因子的影响。

方法

选取云南省第三人民医院在2015年5月至2017年5月收治的73例重症急性胰腺炎患者,按照随机数字表法分为观察组和对照组,对照组在常规治疗基础上加用生长抑素治疗,观察组在常规治疗基础上加用生长抑素联合前列地尔治疗,2周为一疗程;观察两组患者临床疗效、症状缓解时间、血清炎症因子水平、不良反应及死亡率。

结果

观察组临床总有效率为87.5%(28/32),对照组临床总有效率为75.6%(31/41),比较差异具有统计学意义(P<0.05);观察组腹痛缓解时间、肠功能恢复时间、血清淀粉酶(AMY)恢复时间、平均住院时间均低于对照组[(3.2±1.2)d vs.(4.9±1.1)d、(3.7±1.1)d vs.(5.4±1.4)d、(5.8±1.1)d vs.(7.5±1.3)d、(14.8±5.2)d vs.(18.6±4.6)d],差异均具有统计学意义(P<0.05);治疗后两组患者急性生理与慢性健康评分Ⅱ(APACHEⅡ评分)、白细胞(WBC)、超敏C反应蛋白(CRP)、AMY、丙氨酸转氨酶(ALT)、血清肌酐(Cr)水平明显下降,治疗后7 d、14 d观察组APACHEⅡ评分、WBC、CRP、AMY、ALT、Cr水平明显低于对照组[(9.2±2.2)分vs.(10.5±1.5)分、(12.2±3.2)×109/L vs.(13.9±2.9)×109/L、(72.3±17.3)mg/L vs.(106.5±20.1)mg/L、(389.6±57.6)U/L vs.(1066.3±152.4)U/L、(62.9±8.8)U/L vs.(80.4±11.5)U/L、(82.5±18.6)μmol/L vs.(108.6±20.5)μmol/L;(6.8±2.0)分vs.(8.3±2.4)分、(7.5±1.2)×109/L vs.(8.6±1.4)×109/L、(24.2±8.6)mg/L vs.(52.7±15.2)mg/L、(72.6±15.2)U/L vs.(138.2±25.6)U/L、(22.5±6.4)U/L vs.(42.6±12.8)U/L、(46.2±10.4)μmol/L vs.(70.1±16.2)μmol/L],差异均具有统计学意义(P<0.05);治疗后两组患者血清内毒素、肿瘤坏死因子α(TNF-α)、白细胞介素6(IL-6)水平明显下降,观察组血清内毒素、TNF-α、IL-6水平明显低于对照组[(45.3±9.8)Eu/ml vs.(53.2±10.3)Eu/ml、(62.5±13.7)ng/L vs.(76.3±14.2)ng/L、(60.3±11.4)ng/L vs.(81.2±20.9)ng/L],差异均有统计学意义(P均<0.05);观察组死亡率为12.5%(4/32),对照组死亡率为24.4%(10/41),两组比较差异有统计学意义(P<0.05)。

结论

生长抑素联合前列地尔治疗重症急性胰腺炎疗效显著,可有效降低患者血清炎症因子水平,值得临床推广。

Objective

To observe the clinical effect of somatostatin combined with alprostadil in the treatment of severe acute pancreatitis and its influence on serum inflammatory factors.

Methods

Seventy-three patients with severe acute pancreatitis were enrolled in this study from May 2015 to May 2017 in Department of Hepatobiliary Surgery of Third People′s Hospital of Yunnan Province.These patients were randomly divided into observation group and control group according to the random number table method.The patients in control group were treated with routine treatment combined with somatostatin, and the patients in observation group were treated with routine treatment combined with somatostatin and alprostadil for 2 weeks.The clinical efficacy, symptom remission time, serum inflammatory factor level, adverse reaction rate and mortality rate of the two groups were observed.

Results

The total effective rate was 87.5%(28/32)in observation group and 75.6%(31/41)in control group, and the difference was statistically significant(P<0.05). The recovery time of bowel pain, recovery time of intestinal function, recovery time of blood amylase(AMY)and the average hospitalization time of observation group were shorter than those of control group [(3.2±1.2)d vs.(4.9±1.1)d, (3.7±1.1)d vs.(5.4±1.4)d, (5.8±1.1)d vs.(7.5±1.3)d, (14.8±5.2)d vs.(18.6±4.6)d], and the differences were statistically significant(P<0.05). The levels of acute physiology and chronic health evaluationⅡ(APACHEⅡ), white blood count(WBC), C-reactive protein(CRP), AMY, alanine aminotransferase(ALT)and serum creatinine(Cr)in the two groups after treatment declined significantly.The levels of APACHEⅡ, WBC, CRP, AMY, ALT and Cr in observation group were lower than those in control group at 7 days and 14 days after treatment [(9.2±2.2) vs.(10.5±1.5), (12.2±3.2)×109/L vs.(13.9±2.9)×109/L, (72.3±17.3)mg/L vs.(106.5±20.1)mg/L, (389.6±57.6)U/L vs.(1 066.3±152.4)U/L, (62.9±8.8)U/L vs.(80.4±11.5)U/L, (82.5±18.6)μmol/L vs.(108.6±20.5)μmol/L; (6.8±2.0) vs.(8.3±2.4), (7.5±1.2)×109/L vs.(8.6±1.4)×109/L, (24.2±8.6)mg/L vs.(52.7±15.2)mg/L, (72.6±15.2)U/L vs.(138.2±25.6)U/L, (22.5±6.4)U/L vs.(42.6±12.8)U/L, (46.2±10.4)μmol/L vs.(70.1±16.2)μmol/L], and the differences were statistically significant(P<0.05). The levels of endotoxin, tumor necrosis factor-α(TNF-α)and interleukin-6(IL-6)in the two groups declined significantly after treatment.The levels of endotoxin, TNF-αand IL-6 in observation group were lower than those in control group [(45.3±9.8)Eu/ml vs.(53.2±10.3)Eu/ml, (62.5±13.7)ng/L vs.(76.3±14.2)ng/L, (60.3±11.4)ng/L vs.(81.2±20.9)ng/L], and the differences were statistically significant(P<0.05). The mortality rate was 12.5%(4/32)in observation group and 25.4%(10/41)in control group, and the difference was statistically significant(P<0.05).

Conclusion

The effect of somatostatin combined with alprostadil in the treatment of severe acute pancreatitis is obvious, and this treatment can reduce effectively the levels of serum inflammatory factors, which is worthy to be popularized.

表1 两组重症急性胰腺炎患者临床疗效对比(例,%)
表2 两组重症急性胰腺炎患者临床症状改善情况和消化内科住院时间比较(d,±s)
表3 两组重症急性胰腺炎患者血常规及生化指标对比(±s)
表4 两组患者血清炎症因子水平比较(±s)
1
王春友,杨明.急性胰腺炎诊治指南(2014)解读——急性胰腺炎外科诊治难点分析[J].临床外科杂志,2015,8(1): 11-13.
2
刘建,李非.急性胰腺炎患者的诊治及预后[J].中华肝胆外科杂志,2016,22(10): 714-718.
3
刘莉,王芳,於健,等.不同剂量生长抑素对老年重症急性胰腺炎疗效及胃肠动力的影响[J].山东医药,2014,12(24): 62-63.
4
姜素伟,程子安.生长抑素联合泮托拉唑钠治疗重症急性胰腺炎的临床观察[J].中国药房,2015,8(18): 2493-2495.
5
吴林,孔晓霞,郑永平.前列地尔联合腹腔灌洗治疗高脂血症性重症胰腺炎的临床疗效[J].世界华人消化杂志,2015,23(22): 3624-3628.
6
中华医学会消化病学分会胰腺疾病学组.中国急性胰腺炎诊治指南(2013年,上海)[J].中华消化杂志,2013,33(4): 656-660.
7
王海波.不同剂量前列地尔的应用安全性探讨[J].临床医药文献电子杂志,2016,3(7): 1380-1381.
8
郭晓钟,吴春燕.重视急性胰腺炎的病因诊断[J].中国实用内科杂志,2014,34(9): 836-838.
9
伏添,王学莉,童智慧,等.三种评分法对重症急性胰腺炎病人并发胰腺感染预测价值的比较研究[J].肠外与肠内营养,2016,23(3): 129-132.
10
Qi Q, Wang R, Liu L, et al.Comparative effectiveness and tolerability of esomeprazole and omeprazole in gastro-esophageal reflux disease: A systematic review and meta-analysis[J]. Int J Clin Pharmacol Ther, 2015, 53(10): 803-810.
11
陈曦,孙霞,夏兴洲,等.埃索美拉唑联合生长抑素治疗重症胰腺炎的临床研究[J].中国临床药理学杂志,2016,32(14): 1279-1282.
12
杨美荣,刘斌,张国顺,等.生长抑素联合早期血液灌流治疗急性重症胰腺炎临床分析[J].中华实用诊断与治疗杂志,2017,31(2): 145-147.
13
Chen P, Wang W, Zhang Y, et al.Decreased MIZ1 expression in severe experimental acute pancreatitis: A rat study[J]. Dig Dis Sci, 2016, 61(3): 758-766.
14
蔡红慧,邓小梅.前列地尔注射液联合奥曲肽治疗急性重症胰腺炎的疗效及对患者血清TNF-α、IL-6、IL-18、闭合蛋白水平的影响[J].中国生化药物杂志,2017,37(4): 323-325.
15
王华丽,肖江华.生长抑素联合前列地尔治疗重症急性胰腺炎126例疗效分析[J].中国医药指南,2015,13(30): 18-19.
16
张丽贤,袁双珍,孙建顺,等.不同剂量前列地尔在急性胰腺炎患者中的疗效观察[J].河北医药,2014,36(24): 3794-3795.
17
Wang WY, Chen Y, Su X, et al.Resistin-like molecule-αcauses lung injury in rats with acute pancreatitis by activating the PI-3K/Akt-NF-κB pathway and promoting inflammatory cytokine release[J]. Curr Mol Med, 2016, 16(7): 677-687.
18
Shi Q, Chen C, Deng WH, et al.Hydrogen-Rich saline attenuates acute hepatic injury in acute necrotizing pancreatitis by inhibiting inflammation and apoptosis, involving JNK and p38 mitogen-activated protein kinase-dependent reactive oxygen species[J]. Pancreas, 2016, 45(10): 1424-1431.
19
Gillies N, Pendharkar SA, Asrani VM, et al.Interleukin-6 is associated with chronic hyperglycemia and insulin resistance in patients after acute pancreatitis[J]. Pancreatology, 2016, 16(5): 748-755.
20
李卫,周筱筠,卢先州,等.重症急性胰腺炎大鼠血清Apelin、C反应蛋白及肿瘤坏死因子-α水平变化及临床意义[J].中国老年学杂志,2016,36(9): 2080-2082.
21
徐兆军,别华容,田敏,等.生长抑素联合前列地尔对重症急性胰腺炎患者的疗效及对TNF-α、IL-6的影响[J].河北医学,2016,22(2): 266-269.
22
李敏利,张晓华,金鑫鑫,等.前列地尔对重症急性胰腺炎患者早期促炎因子的影响及疗效观察[J].2017,42(2): 140-143.
[1] 陆婷, 范晴敏, 王洁, 万晓静, 许春芳, 董凤林. 超声引导下经皮穿刺置管引流对重症急性胰腺炎的疗效及应用时机的选择[J/OL]. 中华医学超声杂志(电子版), 2024, 21(05): 511-516.
[2] 宫丹丹, 孙飞飞, 于健, 姜晓东. 重症急性胰腺炎死亡风险因素分析及风险评估模型建立[J/OL]. 中华危重症医学杂志(电子版), 2024, 17(01): 19-25.
[3] 孙亚慧, 李甜甜. 在重症急性胰腺炎患者继发感染中调节性T细胞/辅助性T细胞17失衡的机制研究[J/OL]. 中华危重症医学杂志(电子版), 2023, 16(06): 475-480.
[4] 王晓梅, 刘冰, 马丽琼, 卢祖静, 苗建军. 基于LASSO-Cox回归分析的非轻症急性胰腺炎死亡风险列线图预测模型的建立和临床应用效果分析[J/OL]. 中华普通外科学文献(电子版), 2024, 18(01): 44-50.
[5] 党军强, 杨雁灵, 汪庆强, 尚琳, 朱磊, 项红军. 主动经皮穿刺引流治疗重症急性胰腺炎并发急性坏死物积聚的疗效分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 671-674.
[6] 董大红, 周明虎, 李芝朋, 许正峰. 碳青霉烯类抗生素联合呼吸机治疗肺部感染的临床疗效分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 793-796.
[7] 陈慧, 范婷, 李春花, 黄其密, 陈晓英, 翁启明, 彭茹, 唐思, 何佳霖, 陈庆, 王旖旎, 汤玲一. 重症急性胰腺炎并发肺部感染临床分析[J/OL]. 中华肺部疾病杂志(电子版), 2023, 16(06): 856-859.
[8] 李永政, 孟煜凡, 樊知遥, 展翰翔. 胰腺神经内分泌肿瘤新辅助治疗研究进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(04): 481-486.
[9] 王永楠, 汤畅通, 殷杰, 谭溢涛. 微创钻孔引流术与神经内镜血肿清除术治疗临界量基底节脑出血的效果对比分析[J/OL]. 中华神经创伤外科电子杂志, 2024, 10(05): 286-292.
[10] 宋燕秋, 戚桂艳, 杨双双, 周萍. 重症急性胰腺炎肠道菌群特征及早期肠内营养联合微生态制剂治疗的临床价值[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(05): 442-447.
[11] 商倩, 罗静, 卓振山, 苗园园, 吴静, 廖振林. 通腑泻浊法联合生长抑素对内镜逆行胰胆管造影治疗的急性胆源性胰腺炎患者预后的影响[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(05): 437-441.
[12] 丛黎, 马林, 陈旭, 李文文, 张亮亮, 周华亭. 改良CT严重指数联合炎症指标在重症急性胰腺炎患者胰腺感染预测及预后评估中的研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(05): 432-436.
[13] 汪纾羽, 焦茹, 石运涛. 早期肠内营养和微生态免疫肠内营养对重症急性胰腺炎患者肾损伤的预防效果及影响因素[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(02): 132-136.
[14] 王小红, 钱晶, 翁文俊, 周国雄, 朱顺星, 祁小鸣, 刘春, 王萍, 沈伟, 程睿智, 秦璟灏. 巯基丙酮酸硫基转移酶调控核因子κB信号介导自噬对重症急性胰腺炎大鼠的影响及机制[J/OL]. 中华消化病与影像杂志(电子版), 2023, 13(06): 422-426.
[15] 马强, 李军, 苟丽娟. 重症急性胰腺炎miR-21-3p、RUNX3表达水平及对病情发展程度的预测[J/OL]. 中华消化病与影像杂志(电子版), 2023, 13(05): 337-341.
阅读次数
全文


摘要